CrushSCI.com
79.7Average days
71.5Median days
47Fastest days
165Longest days
1182025 publications

Paper Review Records

All Paper Review Records

20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

56 days

Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial

Authors
Juan Miguel Bergua; Pilar Lloret-Madrid; Rebeca Rodríguez-Veiga; Isabel Cano-Ferri; Ferran Vall-llovera; Antonio García-Guiñón; Joaquín Gómez-Espuch; Mercedes Colorado; Ignacio Casas-Avilés; Jordi Esteve; Antonia Sampol; María V. Verdugo; Ágata Almela; Marta Valero; Evelyn Acuña-Cruz; Blanca Boluda; Laura Torres; Joaquín Martínez-López; Eva Barragán; Teresa Cedena; Rosa Ayala; Beatriz Martín-Herreros; Bruno Paiva; David Martínez-Cuadrón; Pau MontesinosShow moreShow less
Affiliations
1. Hospital San Pedro de Alcántara, Cáceres, Spain; 2. Hospital Universitari i Politécnic La Fe, Valencia, Spain; 3. Hospital Universitari Mútua Terrassa, Barcelona, Spain; 4. Hospital Arnau de Vilanova, Lleida, Spain; 5. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; 6. Hospital Universitario Marqués de Valdecilla, Santander, Spain; 7. Hospital Clínic de Barcelona, Barcelona, Spain; 8. Son Espases University Hospital, IdISBa, Palma, Spain; 9. Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain; 10. Hospital Clínico de León, León, Spain; 11. Hospital Arnau de Vilanova, València, Spain; 12. Hospital 12 de Octubre, Universidad imas12, Complutense University, CNIO, Madrid, Spain; 13. Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada, Universidad de Navarra (CIMA), IDISNA, CIBER-ONC CB16/12/00369, Pamplona, SpainShow moreShow less
Source PDF DOI Publisher page
69 days

Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR

Authors
Kiavasch Mohammad Nejad Farid; Ute Hegenbart; Brigitte Neuber; Angela Hückelhoven-Krauss; Marc S. Raab; Carsten Müller-Tidow; Peter Dreger; Stefan Schönland; Anita Schmitt; Uta Elisabeth Höpken; Armin Rehm; Michael SchmittShow moreShow less
Affiliations
1. Medical Faculty University of Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; 2. Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany; 3. Department of Translational Tumorimmunology, Max Delbrück Center for Molecular Medicine (MDC), Berlin, GermanyShow moreShow less
Source PDF DOI Publisher page
119 days

Adjuvant capecitabine-based oral chemotherapy plus trastuzumab as adjuvant therapy in patients with HER2-positive, node-negative breast tumors measuring 1 cm or smaller (ORCHID study)

Authors
Min He; Lei Fan; Yi-Feng Hou; Guang-Yu Liu; Xiu-Zhi Zhu; Li Chen; Yin Liu; Wen-Jia Zuo; Gen-Hong Di; Can-Ming Chen; Zhen Hu; Jun-Jie Li; Kun-Yu Zhang; Li-Chen Tang; Jiong Wu; Yi-Zhou Jiang; Ke-Da Yu; Zhong-Hua Wang; Zhi-Ming ShaoShow moreShow less
Affiliations
1. Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
84 days

A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors

Authors
Yuxiang Ma; Yufeng Guo; Shuang Deng; Haitao Lan; Suxia Luo; Keqiang Zhang; Qingqing Hu; Tao Fu; Pengxiang Wu; Qiuyue Cao; Luyang Zhao; Li Mao; Lieming Ding; Yan Huang; Yuanyuan Zhao; Yang Zhang; Jinhui Xue; Li Zhang; Hongyun ZhaoShow moreShow less
Affiliations
1. Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, China; 2. Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China; 3. Phase I Clinical Research Center, Henan Cancer Hospital, Zhengzhou, China; 4. Department Five of Gynecological Oncology, Hunan Cancer Hospital, Changsha, China; 5. Betta Pharmaceuticals Co., Ltd, Hangzhou, China; 6. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Centre, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
69 days

Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN- ZMYM2::FGFR1

Authors
Tino Vollmer; Christoph Schell; Milena Pantic; Dietmar Pfeifer; Robert Zeiser; Khalid ShoumariyehShow moreShow less
Affiliations
1. Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 2. Institute of Surgical Pathology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyShow moreShow less
Source PDF DOI Publisher page
165 days

Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor?

Authors
Chantal Lucini; Isabella Sponseiler; Anna-Maria Bandian; Julia Senkiv; Thomas LionShow moreShow less
Affiliations
1. St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria; 2. Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; 3. Department of Pediatrics, Medical University of Vienna, Vienna, Austria; 4. St. Anna Children´s Cancer Research Institute, Vienna, AustriaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Journal of Hematology & Oncology take to review a manuscript?

As of 2026-11-18, CrushSCI has 20 complete review records for Journal of Hematology & Oncology. The fastest paper went from submission to acceptance in 47 days (The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026, received 2026-06-04, accepted 2026-07-21); the slowest took 165 days. The average is 79.7 days and the median is 71.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.